论文部分内容阅读
目的 观察~(125)Ⅰ标记基因重组融合蛋白LTB-UreB灌喂BALB/c小鼠后的体内分布。方法 采用氯胺T氧化法标记rLTB-UreB,Sephadex-G25凝胶过滤纯化,纸层析鉴定放射化学纯度及比活度。将BALB/c小鼠随机分为PBS口服空白对照组、Na~(125) Ⅰ口服对照组和~(125)Ⅰ-rLTB-UreB实验组,于不同时间采集标本,γ放射计数器检测CPM(每分钟计数值),SPSS分析结果。结果 纯化后的标记蛋白纯度>90％。实验组PP结和肠系膜淋巴结CPM升高,与对照组比较差异有非常显著意义。结论 ~(125)Ⅰ标记融合蛋白口服后可在肠道粘膜下淋巴组织沉积,为融合蛋白作为幽门螺杆菌口服疫苗候选抗原提供重要实验依据。
Objective To observe the in vivo distribution of ~ (125) Ⅰ marker gene recombinant fusion protein LTB-UreB in BALB / c mice. Methods Chloramine T oxidation method was used to label rLTB-UreB and Sephadex-G25 gel filtration. The radiochemical purity and specific activity were identified by paper chromatography. BALB / c mice were randomly divided into PBS control group, Na ~ (125) I oral control group and ~ (125) I-rLTB-UreB experimental group. The specimens were collected at different time points. Minute count), SPSS analysis results. Results The purity of purified protein was> 90%. The experimental group PP junction and mesenteric lymph nodes CPM increased, compared with the control group has a very significant difference. Conclusion 125I Ⅰ fusion protein can be deposited in intestinal submucosal lymphocytes after oral administration, providing an important experimental evidence for the fusion protein as candidate antigen for oral vaccine of Helicobacter pylori.